Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 5/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19923558 | 0.85 | ELANE (0.41) | ELANECACNA1BAPBA1PGRGAA | |
| SCHEMBL19923536 | 0.85 | ELANE (0.49) | ELANECACNA1BAPBA1PGRGAA | |
| SCHEMBL19923599 | 0.84 | ELANE (0.41) | ELANECACNA1BAPBA1PGRGAA | |
| SCHEMBL19923430 | 0.83 | ELANE (0.45) | ELANECACNA1BAPBA1PGRGAA | |
| SCHEMBL19923706 | 0.81 | ALDH1A1 (0.39) | ELANEGAAALDH1A1HSD11B1HTR1A | |
| SCHEMBL19923559 | 0.81 | HTR1A (0.42) | GAAALDH1A1HTR1AHTR6BRD4 | |
| SCHEMBL19923654 | 0.79 | ELANE (0.47) | ELANECACNA1BAPBA1PGRGAA | |
| SCHEMBL19923692 | 0.78 | ELANE (0.51) | ELANEMEN1KMT2A | |
| SCHEMBL17716274 | 0.76 | ELANE (0.52) | ELANECACNA1BAPBA1PGRGAA | |
| SCHEMBL19923609 | 0.72 | ELANE (0.40) | ELANEPGRGAAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10899718-B2 | Polymers functionalized with N-protected hydantoin compounds | BRIDGESTONE CORPORATION (JP) | 2021-01-26 | — | — | US | claimed |
| US-20180065935-A1 | POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2018-03-08 | — | — | US | claimed |
| US-10899718-B2 | Polymers functionalized with N-protected hydantoin compounds | BRIDGESTONE CORPORATION (JP) | 2021-01-26 | — | — | US | disclosed |
| US-20180065935-A1 | POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065935-A1 | POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS | PARG, HNMT, PARN | ELANE 1249/4885CACNA1B 3477/4885APBA1 1514/4885 |
| US-10899718-B2 | Polymers functionalized with N-protected hydantoin compounds | HNMT, PARG, PAM | ELANE 1276/4885CACNA1B 3344/4885APBA1 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.